tradingkey.logo

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

ReutersJun 24, 2025 12:36 PM

- Veru Inc VERU.O:

  • VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION

  • VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION

  • VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION

  • VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS

  • VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM

  • VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI